Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Cobicistat
100%
Darunavir
100%
Single Tablet
100%
Tenofovir Alafenamide
100%
Emtricitabine
100%
Co-formulation
75%
Protease Inhibitors
50%
Nave
50%
Once-daily
50%
Fixed-dose Combination
50%
Clinical Trials
25%
Infectious Diseases
25%
HIV Infection
25%
Area Cover
25%
Virus
25%
Expert Opinion
25%
AIDS/HIV
25%
Antiviral Drugs
25%
Drug Adherence
25%
Safety Profile
25%
PubMed
25%
Viral Suppression
25%
Life-sustaining Treatment
25%
HIV Eradication
25%
Second-line Antiretroviral Therapy
25%
Fixed-dose Combination Therapy
25%
Pill Burden
25%
Treatment-experienced Patients
25%
Single pill
25%
Antiviral Efficacy
25%
Treatment of HIV Infection
25%
Combination Regimen
25%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Tablet
100%
Cobicistat
100%
Darunavir
100%
Emtricitabine
100%
Tenofovir Alafenamide
100%
Proteinase Inhibitor
50%
Antivirus Agent
50%
Human Immunodeficiency Virus Infection
50%
Clinical Trial
25%
Infection
25%
Combination Therapy
25%
Cobicistat Plus Darunavir Plus Emtricitabine Plus Tenofovir Alafenamide
25%
Reducing Agent
25%